Aim: The aim of the present study to compare the safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% inallergic conjunctivitis. Methods : A total of 120 patients with mild or moderate allergic conjunctivitis were randomized into three groups with an allocation ratio of 1:1:1 using computer‑generated random number sequence to receive topical anti-allergic medication for 14 days as Group 1: Topical 0.25% Alcaftadine eye drops OD, Group 2: Topical 0.2% Olopatadine eye drops OD and Group 3: Topical 1.5% Bepotastine besilate eye drops BID. Patients were examined and their baseline symptoms and signs (TOSS) were recorded. Results: A total of 150 patients were screened for the study of whom 120 patients with mild or moderate allergic conjunctivitis were included in this study. The total ocular symptom score (TOSS) showed a consistent decrease in subsequent visit in all the Groups and it was statistically significant, when compared from baseline to 14th day in all the groups (p = 0.0007). The difference in mean TOSS between (Group A) Alcaftadine and (Group C) bepotastine treatment groups was observed atthe third day of follow‑up. This showed early relief of allergic conjunctivitis symptoms by bepotastine (5.87 ± 1.66) comparedto Alcaftadine (mean (6.12 ± 1.69) and olopatadine (6.12 ± 1.69) but this was not statistically significant. Alcaftadine was found to be better than olopatadine in reducing the Allergic Conjunctivitissymptoms using TOSS score at 14th ‑day visit (p < 0.5). Although there is no significant difference between bepotastine andAlcaftadine groups, bepotastine showed a better reduction of symptoms compared to Olopatadine group usingTOSS score at 14th ‑day visit (p<0.1). Conjunctival hyperaemiahad reduced in all the treatment groups but there was a significant reduction in Alcaftadine and Bepotastine treatmentgroups at 14th day compared to olopatadine group (p = 0.0029). Conclusion: All three topical ophthalmic medications used in the study are safe and effective in the treatment of allergic conjunctivitis. However, Bepotastine and Alcaftadine appear to outweigh Olopatadinein resolving the symptoms of allergic conjunctivitis.